Bayer Receives FDA Fast-Track Designation for Next-Generation Anticoagulant
February 18th 2022Asundexian is an oral factor XIa inhibitor currently under phase 2 trials for potential secondary thrombosis prevention in patients with non-cardioembolic ischemic stroke, atrial fibrillation, or recent myocardial infarction.